Ticker LaunchIPO · APRE
Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. (APRE) priced its initial public offering on Oct 4, 2019 at $15.00 per share, within its $14.00–$16.00 range, raising $85M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $298.1M. J.P. Morgan was lead-left underwriter, joined by Morgan Stanley and RBC Capital Markets. Sidley Austin advised the company and Davis Polk advised the underwriters.
- Status
- IPO
- Ticker
- APRE
- Exchange
- Nasdaq Global Select
- Priced
- Oct 4, 2019
- IPO price
- $15.00
- Price range
- $14.00–$16.00
- Raised
- $85M
- Market cap at IPO price
- $298.1M
- First filed
- Sep 6, 2019
- Underwriters
- J.P. Morgan, Morgan Stanley and RBC Capital Markets
- Company counsel
- Sidley Austin
- Underwriters' counsel
- Davis Polk
- Sector
- Biotech & pharma
- Country / state
- PA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Sep 6, 2019
- Latest amendment Oct 2, 2019
- Final prospectus (424B4) Oct 4, 2019
- All filings on EDGAR CIK 1781983
Other Biotech & pharma IPOs in 2019
- Innate Pharma SAIPHA · Oct 18, 2019
- BioNTech SEBNTX · Oct 11, 2019 · $150M
- Vir Biotechnology, Inc.VIR · Oct 11, 2019 · $142.9M
- Korro Bio, Inc.FREQ · Oct 4, 2019 · $84M
- Viela Bio, Inc.VIE · Oct 4, 2019 · $150.1M
- IGM Biosciences, Inc.IGMS · Sep 18, 2019 · $175M